Celsion Co. (NASDAQ:CLSN) Short Interest Up 236.1% in April

Celsion Co. (NASDAQ:CLSN – Get Rating) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 195,300 shares, a growth of 236.1% from the March 31st total of 58,100 shares. Currently, 2.8% of the shares of the company are sold short. Based on an average trading volume of 315,600 shares, the days-to-cover ratio is presently 0.6 days.

Shares of CLSN opened at $3.05 on Thursday. The company has a market cap of $17.60 million, a PE ratio of -0.78 and a beta of 2.11. The company has a current ratio of 7.67, a quick ratio of 7.67 and a debt-to-equity ratio of 0.10. The stock has a 50-day moving average price of $4.67 and a 200-day moving average price of $8.11. Celsion has a 12-month low of $2.97 and a 12-month high of $23.25.

CLSN has been the topic of a number of research reports. StockNews.com started coverage on Celsion in a report on Wednesday. They issued a “hold” rating on the stock. HC Wainwright started coverage on Celsion in a research note on Wednesday, April 13th. They set a “buy” rating and a $16.00 target price for the company.

Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC raised its holdings in Celsion by 181.8% in the third quarter. Jane Street Group LLC now owns 36,055 shares of the biotechnology company’s stock worth $33,000 after buying an additional 23,261 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in Celsion in the fourth quarter worth about $35,000. Two Sigma Advisers LP purchased a new position in Celsion in the third quarter worth about $68,000. Virtu Financial LLC purchased a new position in Celsion in the fourth quarter worth about $55,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Celsion during the fourth quarter valued at approximately $59,000. Institutional investors own 10.75% of the company’s stock.

Celsion Company Profile (Get Rating)

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.

Further Reading